M
Ming Zhu
Researcher at AbbVie
Publications - 223
Citations - 6091
Ming Zhu is an academic researcher from AbbVie. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 26, co-authored 54 publications receiving 4700 citations. Previous affiliations of Ming Zhu include Singapore Ministry of Health & Emory University.
Papers
More filters
Journal ArticleDOI
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts,Matthew S. Davids,John M. Pagel,Brad S. Kahl,Soham D. Puvvada,John F. Gerecitano,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Jennifer R. Brown,Lori A. Gressick,Shekman Wong,Martin Dunbar,Ming Zhu,Monali Desai,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,William G. Wierda,John F. Seymour,John F. Seymour +20 more
TL;DR: Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.
Journal ArticleDOI
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva,Daniel A. Pollyea,Jalaja Potluri,Brenda Chyla,Leah Hogdal,Todd Busman,Evelyn McKeegan,Ahmed Salem,Ming Zhu,Justin L. Ricker,William Blum,Courtney D. DiNardo,Tapan M. Kadia,Martin Dunbar,Rachel Kirby,Nancy Falotico,Joel D. Leverson,Rod A. Humerickhouse,Mack Mabry,Richard Stone,Hagop M. Kantarjian,Anthony Letai +21 more
TL;DR: Venetoclax monotherapy demonstrated clinical activity in patients with AML (relapsed/refractory or unfit for intensive chemotherapy) with a tolerable safety profile in this phase II study.
Journal ArticleDOI
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer,Barbara Eichhorst,Johannes Schetelig,Steven Coutre,John F. Seymour,Talha Munir,Soham D. Puvvada,Clemens M. Wendtner,Andrew W. Roberts,Wojciech Jurczak,Stephen P. Mulligan,Sebastian Böttcher,Mehrdad Mobasher,Ming Zhu,Monali Desai,Brenda Chyla,Maria Verdugo,Sari H. Enschede,Elisa Cerri,Rod A. Humerickhouse,Gary Gordon,Michael Hallek,William G. Wierda +22 more
TL;DR: Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic option for this very poor prognosis population.
Journal ArticleDOI
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids,Andrew W. Roberts,Andrew W. Roberts,John F. Seymour,John F. Seymour,John M. Pagel,Brad S. Kahl,William G. Wierda,Soham D. Puvvada,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Ahmed Salem,Ahmed Salem,Martin Dunbar,Ming Zhu,Franklin Peale,Jeremy A. Ross,Lori A. Gressick,Monali Desai,Su Young Kim,Maria Verdugo,Rod A. Humerickhouse,Gary Gordon,John F. Gerecitano +24 more
TL;DR: Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes, and 1,200 mg was determined to be the recommended single- agent dose for future studies in FL and DLBCL.
Journal ArticleDOI
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
Saranya Sridhar,Alex Luedtke,Edith Langevin,Ming Zhu,Matthew Bonaparte,Tifany Machabert,Stephen Savarino,Betzana Zambrano,Annick Moureau,Alena Khromava,Zoe Moodie,Ted Westling,Cesar Mascareñas,Carina Frago,Margarita Cortés,Danaya Chansinghakul,Fernando Noriega,Alain Bouckenooghe,Josh Chen,Su-Peing Ng,Peter B. Gilbert,Sanjay Gurunathan,Carlos A. DiazGranados +22 more
TL;DR: CYD‐TDV protected against severe VCD and hospitalization for VCD for 5 years in persons who had exposure to dengue before vaccination, and there was evidence of a higher risk of these outcomes in vaccinated people who had not been exposed to d Dengue.